Literature DB >> 12491062

Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level?

Peter Vaupel1, Oliver Thews, Arnulf Mayer, Susanne Höckel, Michael Höckel.   

Abstract

BACKGROUND: Tumor hypoxia has been linked to the development of treatment resistance, tumor progression, and poor prognosis. Since anemia is a major causative factor for the development of hypoxia, the association between blood hemoglobin concentration (cHb) and tumor oxygenation was examined in this study. PATIENTS AND METHODS: Pretreatment O(2) tension (pO(2)) measurements were performed in 59 primary carcinomas of the uterine cervix in which a stringent histopathologic examination of the electrode tracks was mandatory in order to exclude measurements in necrotic, stromal or normal cervical tissue. In addition, pO(2) readings in twelve primary cancers and 17 local recurrences of vulvar cancers were included in this study. cHb was determined at the time of pO(2) measurements.
RESULTS: Data presented clearly show that an optimal Hb level with regard to the median pO(2) values of cervical and vulvar cancers should prevail at cHb values of between 12 and 14 g/dl (7.45-8.60 mmol/l). In anemic patients (cHb < 12 g/dl), the deterioration of the tumor oxygenation status can be explained by a reduced O(2) transport capacity. At cHb values > 14 g/dl, a worsening of the tumor oxygenation is apparent, most probably due to a drop in perfusion following a drastic increase in viscous resistance to flow. This pathogenetic mechanism is thought to counteract and finally to abrogate the high O(2) transport capacity in this cHb range.
CONCLUSIONS: This study suggests that cHb values of between 12 and 14 g/dl are optimal with regard to the oxygenation status in the tumor entities investigated, a finding which may have far-reaching implications in the clinical setting.

Entities:  

Mesh:

Year:  2002        PMID: 12491062     DOI: 10.1007/s00066-002-1081-x

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  15 in total

1.  Prognostic impact of VEGF and VEGF receptor 1 (FLT1) expression in patients irradiated for stage II/III non-small cell lung cancer (NSCLC).

Authors:  Dirk Rades; Cornelia Setter; Juergen Dunst; Olav Dahl; Steven E Schild; Frank Noack
Journal:  Strahlenther Onkol       Date:  2010-04-26       Impact factor: 3.621

2.  Predictors of sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma.

Authors:  Yan Yi; Baosheng Li; Hongfu Sun; Zicheng Zhang; Heyi Gong; Hongsheng Li; Wei Huang; Zhongtang Wang
Journal:  Tumour Biol       Date:  2010-05-20

Review 3.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.

Authors:  S R McKeown
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

4.  Impact of erythropoietin on the reduction of blood transfusions and on survival of lung cancer patients receiving first-line chemotherapy.

Authors:  P J Fonseca; E Esteban; P de Vicente; M Luque; B Llorente; M Capelán; J P Berros; G Crespo; A J Lacave
Journal:  Clin Transl Oncol       Date:  2008-07       Impact factor: 3.405

5.  Recombinant human erythropoietin attenuates weight loss in a murine cancer cachexia model.

Authors:  H K van Halteren; G P A Bongaerts; C A M Verhagen; Y J L Kamm; J L Willems; G J Grutters; J P Koopman; D J Th Wagener
Journal:  J Cancer Res Clin Oncol       Date:  2004-01-27       Impact factor: 4.553

6.  Pre-radiotherapy Haemoglobin Level is A Prognosticator in Locally Advanced Head and Neck Cancers Treated with Concurrent Chemoradiation.

Authors:  Rajesh Kar Narayanaswamy; Mahadev Potharaju; A N Vaidhyswaran; Karthikeyan Perumal
Journal:  J Clin Diagn Res       Date:  2015-06-01

Review 7.  Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.

Authors:  Julia Bohlius; Kurt Schmidlin; Corinne Brillant; Guido Schwarzer; Sven Trelle; Jerome Seidenfeld; Marcel Zwahlen; Mike J Clarke; Olaf Weingart; Sabine Kluge; Margaret Piper; Maryann Napoli; Dirk Rades; David Steensma; Benjamin Djulbegovic; Martin F Fey; Isabelle Ray-Coquard; Volker Moebus; Gillian Thomas; Michael Untch; Martin Schumacher; Matthias Egger; Andreas Engert
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

8.  Srinagarind Hospital experience in concurrent chemoradiation for 100 patients with stage IB2 to IVA uterine cervical cancer.

Authors:  Thumwadee Tangsiriwatthana; Bandit Chumworathayi; Pissamai Yuenyao; Sanguanchoke Luanratanakorn; Jeerichuda Pattamadilok
Journal:  Radiat Med       Date:  2007-12-25

9.  Radiotherapy Planning and Molecular Imaging in Lung Cancer.

Authors:  Angelina Filice; Massimiliano Casali; Patrizia Ciammella; Marco Galaverni; Federica Fioroni; Cinzia Iotti; Annibale Versari
Journal:  Curr Radiopharm       Date:  2020

10.  Allogeneic blood transfusion given before radiotherapy is associated with the poor clinical outcome in patients with cervical cancer.

Authors:  Myong Cheol Lim; Joo-Young Kim; Tae-Hyun Kim; Sohee Park; Sun-Young Kong; Jung-Hyun Yoon; Sokbom Kang; Sang-Soo Seo; Sang Yoon Park
Journal:  Yonsei Med J       Date:  2008-12-31       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.